Create Free Account

By creating account you will get access to hot stocks & personalised emails

Prescient Therapeutics Ltd

Healthcare AU PTX

0.042AUD
-(-%)

Last update at 2024-12-19T04:35:00Z

Day Range

0.040.04
LowHigh

52 Week Range

0.040.07
LowHigh

Fundamentals

  • Previous Close 0.04
  • Market Cap33.02M
  • Volume136095
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.18570M
  • Revenue TTM3.71M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM 2.43M
  • Diluted EPS TTM-0.01

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -7.00450M -5.11718M -4.14882M -3.32119M -3.79723M
Minority interest - - - - -
Net income -7.00450M -5.12371M -5.38205M -4.43138M -3.79723M
Selling general administrative 3.66M 3.70M 2.93M 1.73M 1.86M
Selling and marketing expenses - - - - -
Gross profit - - - - 1.65M
Reconciled depreciation 0.00209M 0.00140M 0.00047M 0.00090M -
Ebit -9.88808M -5.11064M -4.13820M -3.31790M -3.79393M
Ebitda -9.88599M -5.10924M -4.13773M -3.31700M -3.79393M
Depreciation and amortization 0.00209M 0.00140M 0.00047M 0.00090M -
Non operating income net other - - - - -
Operating income -9.88808M -5.11064M -4.13820M -3.31790M -3.79393M
Other operating expenses 9.89M 7.10M 5.43M 4.49M 5.55M
Interest expense - 0.00653M 0.01M 0.00419M 0.00330M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.46M 0.04M 0.07M 0.02M 0.03M
Net interest income 0.46M 0.04M 0.06M -0.00419M 0.07M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.46119M 0.00653M 1.23M 1.11M -
Total revenue 0.46M 0.04M 0.07M 0.07M 0.07M
Total operating expenses 9.89M 7.10M 5.43M 4.49M 5.55M
Cost of revenue - - - - -
Total other income expense net 2.42M -0.00653M -0.01061M -0.00329M -0.00330M
Discontinued operations - - - - -
Net income from continuing ops -7.00450M -5.11718M -4.14882M -3.32119M -3.79723M
Net income applicable to common shares -7.00450M -5.11718M -4.14882M -3.32119M -3.79723M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 20.39M 28.11M 17.62M 20.97M 12.07M
Intangible assets 1.65M 3.37M 3.37M 3.37M 3.37M
Earning assets - - - - -
Other current assets 0.31M 2.37M 1.64M 1.19M 1.03M
Total liab 2.33M 2.03M 0.86M 0.54M 0.88M
Total stockholder equity 18.07M 26.08M 16.76M 20.43M 11.19M
Deferred long term liab - - - - -
Other current liab 0.27M 0.25M 0.30M 0.28M 0.38M
Common stock 93.27M 93.25M 77.26M 76.67M 63.93M
Capital stock 93.27M 93.25M 77.26M 76.67M 63.93M
Retained earnings -77.39700M -69.31332M -62.45208M -57.50762M -53.45810M
Other liab - 0.00622M 0.05M 0.03M 0.02M
Good will - - - - -
Other assets 0.00000M - - - -
Cash 10.49M 5.90M 12.26M 16.10M 7.36M
Cash and equivalents - 4.00M - - -
Total current liabilities 2.32M 2.03M 0.81M 0.51M 0.86M
Current deferred revenue - - - -0.16583M -0.15688M
Net debt -10.16270M -5.89543M -12.26384M -15.93168M -7.20020M
Short term debt 0.33M 0.00000M 0.00000M 0.17M 0.16M
Short long term debt 0.33M - - 0.17M 0.16M
Short long term debt total 0.33M - - 0.17M 0.16M
Other stockholder equity - -23.93308M -14.81218M -19.16355M -10.47232M
Property plant equipment - 0.00282M 0.00490M 0.00188M 0.00004M
Total current assets 18.74M 24.74M 14.25M 17.60M 8.71M
Long term investments - - - - -
Net tangible assets - 22.71M 13.40M 17.06M 7.82M
Short term investments 4.02M 16.02M 0.02M 0.02M 0.02M
Net receivables 3.92M 0.21M 0.08M 0.05M 0.03M
Long term debt - - - - -
Inventory - 0.25M 0.24M 0.24M 0.27M
Accounts payable 1.72M 1.78M 0.51M 0.23M 0.48M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.19M 2.14M 1.95M 1.26M 0.72M
Additional paid in capital - - - - -
Common stock total equity - - - - 63.93M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M -3.36971M -3.37180M -3.36877M -3.36693M
Deferred long term asset charges - - - - -
Non current assets total 1.65M 3.37M 3.37M 3.37M 3.37M
Capital lease obligations - - - - -
Long term debt total - 0.00000M 0.00000M 0.00000M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -16.00000M -0.00443M -0.00231M -16.00000M -
Change to liabilities 1.16M 0.39M -0.38523M 0.27M 0.14M
Total cashflows from investing activities -16.00000M -0.00443M -0.00231M -0.00231M -0.00231M
Net borrowings - -0.16583M 0.00895M 0.00895M -0.05605M
Total cash from financing activities 15.83M 0.43M 12.75M 12.75M 8.37M
Change to operating activities -0.68720M -0.38777M -0.09677M 0.49M -0.74650M
Net income -7.00450M -5.11718M -4.14882M -3.32119M -3.79723M
Change in cash -6.36841M -3.83367M 8.74M -2.28256M 4.15M
Begin period cash flow 12.26M 16.10M 7.36M 9.64M 5.49M
End period cash flow 5.90M 12.26M 16.10M 7.36M 9.64M
Total cash from operating activities -6.19100M -4.31266M -3.97003M -2.31718M -4.19547M
Issuance of capital stock 16.53M 0.59M 13.58M - 9.12M
Depreciation 0.00209M 0.00140M 0.00047M 0.00090M 0.00134M
Other cashflows from investing activities - - - - -
Dividends paid - - 12.75M - -
Change to inventory - - - - -
Change to account receivables -0.13106M -0.02400M -0.02387M 0.09M -0.07167M
Sale purchase of stock - 0.59M -0.83655M -0.83655M -0.69949M
Other cashflows from financing activities -0.69782M -0.00443M 12.77M 0.02M -0.69949M
Change to netincome 0.47M 0.83M 0.68M 0.15M 0.27M
Capital expenditures 0.00000M 0.00443M 0.00231M 0.00231M 0.00231M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.13106M -0.02400M -0.02387M 0.09M 1.04M
Stock based compensation 0.46M 0.88M 0.65M 0.19M -
Other non cash items 0.81M 0.80M 0.18M 1.00M 3.80M
Free cash flow -6.19100M -4.31709M -3.97234M -2.31718M -4.19547M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PTX
Prescient Therapeutics Ltd		 - -% 0.04 - - 8.89 1.83 - -8.358
CSL
CSL Ltd		 -3.45 1.22% 278.79 32.86 33.00 9.11 5.02 6.65 20.64
TLX
Telix Pharmaceuticals Ltd		 -0.07 0.27% 25.67 161.73 75.19 12.58 19.98 12.52 109.28
MSB
Mesoblast Ltd		 1.07 54.04% 3.05 - 454.55 312.43 2.49 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.36 2.79% 12.54 13.51 35.21 8.91 5.13 6.48 8.45

Reports Covered

Stock Research & News

View All

Profile

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-100, a first in class compound with the ability to block an cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.

Prescient Therapeutics Ltd

100 Albert Road, Melbourne, VIC, Australia, 3205

Key Executives

Name Title Year Born
Mr. Steven Lee Yatomi-Clarke MD, CEO & Director NA
Ms. Melanie Jaye Leydin B.Bus, C.A., CA CFO & Company Sec. 1973
Ms. Leanne West Director of Clinical Affairs & Operations NA
Dr. Terrence G. Chew Chief Medical Officer 1947
Ms. Rebecca Lim Sr. VP of Scientific Affairs NA
Ms. Melanie Jaye Leydin B.Bus, C.A. CFO & Company Secretary 1973
Ms. Melanie Jaye Leydin B.Bus, C.A. CFO & Company Secretary 1973
Ms. Rebecca Lim Senior Vice President of Scientific Affairs NA
Ms. Melanie Jaye Leydin B.Bus, C.A. CFO & Company Secretary 1973
Ms. Rebecca Lim Senior Vice President of Scientific Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.